Related Experiment Videos
[HIV-related dementia].
1Alzheimer's Disease Research Center, UCLA Department of Neurology, Los Angeles, USA. frederic.assal@hcuge.ch
Revue Medicale De La Suisse Romande
|April 21, 2004
Summary
HIV-Dementia (HIV-D), a global cause of cognitive decline, is increasingly seen in patients with higher CD4 counts despite effective treatments. This neurodegenerative condition involves cognitive, behavioral, and motor deficits, driven by immune and inflammatory responses in the brain.
Area of Science:
- Neuroscience
- Immunology
- Virology
Context:
- HIV-Dementia (HIV-D) remains a significant global health concern.
- Highly active retroviral therapy has reduced overall prevalence but shifted patient demographics.
- An increasing proportion of HIV-D cases present with higher CD4+ T cell counts.
Purpose:
- To summarize the current understanding of HIV-D, including its pathogenesis, diagnosis, and neuropathology.
- To highlight the changing clinical landscape of HIV-D.
- To discuss potential future therapeutic strategies.
Summary:
- HIV-D is characterized by cognitive, behavioral, and motor deficits, often preceded by HIV-associated minor cognitive impairment.
- Diagnosis involves neurological assessment, brain imaging, cerebrospinal fluid analysis, and immunologic parameters.
- Neuropathology reveals brain inflammation and atrophy, with direct or indirect viral attack on astrocytes and neurons via macrophage activation.
Impact:
- HIV-D is an immunologic, inflammatory, and neurodegenerative disease.
- Understanding the immunopathogenesis is crucial for developing targeted therapies.
- Future treatments may focus on blocking cell-cell signaling or apoptosis to mitigate neurodegeneration.